Tom Hancock, head of focused equity and portfolio manager of the firm’s $29bn quality strategy, tells FSA how it has managed to consistently outperform and where he currently sees opportunities.

Tom Hancock, head of focused equity and portfolio manager of the firm’s $29bn quality strategy, tells FSA how it has managed to consistently outperform and where he currently sees opportunities.
Most healthcare investors focus on binary bets around clinical trials instead of buying profitable healthcare businesses, according to AllianceBernstein’s Vinay Thapar.
As artificial intelligence permeates through the healthcare industry, Bellevue Group favours the companies that stand to gain the most.
Janus Henderson’s Andy Acker suggests the opportunity for healthcare outperformance is becoming more promising after last year’s difficulties.
42% of fund selectors rank China as their top concern compared with 21% globally, according to Natixis Investment Managers’ survey.
The Novo Nordisk share price is up 51% over the past year, while Eli Lilly is up 84%.
After a rough ride during 2021 and 2022, the PGIM Jennison Global Opportunity fund is outperforming in 2023.
Fund managers at Janus Henderson and abrdn share why they are bullish on the healthcare sector.
Dividend kings, JP Morgan’s active drive, Wellington Management’s biopharma video, M&G’s investment mega trends, soaring hedge fund pay, Ray Dalio’s biography, Ottawa madness and much more.
AXA IM identifies two areas within robotech that are likely to weather the recessionary storm.
Part of the Mark Allen Group.